Trials / Completed
CompletedNCT00174252
Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age
Evolution of IGF-1 in Children Born Small for Gestational Age and With Growth Retardation, Treated by Genotonorm Especially Evolution After Dose Adaptation.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 4 Years – 9 Years
- Healthy volunteers
- Not accepted
Summary
To estimate the percentage of children with serum IGF-1 \> 2 standard deviation (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Genotonorm (Somatropin) | 0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2005-09-15
- Last updated
- 2010-06-15
- Results posted
- 2010-06-04
Locations
22 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00174252. Inclusion in this directory is not an endorsement.